BACKGROUND: Quality measures of evidence-based medications post-myocardial infarction have focused on prescription at hospital discharge. Yet survival benefits of these medications are best realized with sustained therapy. We sought to examine long-term beta-blocker adherence over the first year after myocardial infarction in patients with commercial health insurance and prescription drug benefits. METHODS: This multicenter analysis examined health plan records from members of 11 health plans who had myocardial infarction in 2001, survived at least 1 year, and maintained insurance coverage (N = 17,035). The primary outcome measure was adherence to beta-blockers (defined as prescription claims covering > or = 75% of days) for 360 days post-discharge. We also examined associations with adherence--time from discharge, health plan product (commercial or Medicare + Choice [M + C]), age (35-64 or > or = 65), sex, and region. RESULTS: For 360 days after discharge, only 45% of patients were adherent to beta-blockers, with the biggest drop in adherence between 30 and 90 days. In a multivariable model, statistically significant predictors of lower adherence were participation in M + C product, residence in the Southeast, and age (driven by young participants in M + C and young females in commercial products). CONCLUSIONS: In a population of patients with health insurance and prescription drug coverage, adherence to beta-blocker therapy in the first year after myocardial infarction is poor, indicating that factors other than medication cost are important determinants of long-term adherence. Quality improvement initiatives focused on long-term adherence are needed to realize maximal benefit from medical therapy in post-myocardial infarction patients.
BACKGROUND: Quality measures of evidence-based medications post-myocardial infarction have focused on prescription at hospital discharge. Yet survival benefits of these medications are best realized with sustained therapy. We sought to examine long-term beta-blocker adherence over the first year after myocardial infarction in patients with commercial health insurance and prescription drug benefits. METHODS: This multicenter analysis examined health plan records from members of 11 health plans who had myocardial infarction in 2001, survived at least 1 year, and maintained insurance coverage (N = 17,035). The primary outcome measure was adherence to beta-blockers (defined as prescription claims covering > or = 75% of days) for 360 days post-discharge. We also examined associations with adherence--time from discharge, health plan product (commercial or Medicare + Choice [M + C]), age (35-64 or > or = 65), sex, and region. RESULTS: For 360 days after discharge, only 45% of patients were adherent to beta-blockers, with the biggest drop in adherence between 30 and 90 days. In a multivariable model, statistically significant predictors of lower adherence were participation in M + C product, residence in the Southeast, and age (driven by young participants in M + C and young females in commercial products). CONCLUSIONS: In a population of patients with health insurance and prescription drug coverage, adherence to beta-blocker therapy in the first year after myocardial infarction is poor, indicating that factors other than medication cost are important determinants of long-term adherence. Quality improvement initiatives focused on long-term adherence are needed to realize maximal benefit from medical therapy in post-myocardial infarctionpatients.
Authors: Eric D Peterson; P Michael Ho; Mary Barton; Craig Beam; L Hayley Burgess; Donald E Casey; Joseph P Drozda; Gregg C Fonarow; David Goff; Kathleen L Grady; Dana E King; Marjorie L King; Frederick A Masoudi; David R Nielsen; Stephen Stanko Journal: Circulation Date: 2014-11-03 Impact factor: 29.690
Authors: Ayse Akincigil; John R Bowblis; Carrie Levin; Saira Jan; Minalkumar Patel; Stephen Crystal Journal: J Gen Intern Med Date: 2007-10-06 Impact factor: 5.128
Authors: Layla Parast; Brian Doyle; Cheryl L Damberg; Kanaka Shetty; David A Ganz; Neil S Wenger; Paul G Shekelle Journal: J Gen Intern Med Date: 2015-01-07 Impact factor: 5.128
Authors: Ankur Pandya; Stephen Sy; Sylvia Cho; Sartaj Alam; Milton C Weinstein; Thomas A Gaziano Journal: Med Decis Making Date: 2017-05-10 Impact factor: 2.583
Authors: Niteesh K Choudhry; Soko Setoguchi; Raisa Levin; Wolfgang C Winkelmayer; William H Shrank Journal: Pharmacoepidemiol Drug Saf Date: 2008-12 Impact factor: 2.890
Authors: Jia-Rong Wu; Debra K Moser; Marla J De Jong; Mary Kay Rayens; Misook L Chung; Barbara Riegel; Terry A Lennie Journal: Am Heart J Date: 2008-12-24 Impact factor: 4.749